About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5779643
Allelic
Composition
Braftm1Cpri/Braftm1Cpri
Tg(TPO-cre)1Shk/0
Genetic
Background
involves: 129P2/OlaHsd * FVB/NCr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Cpri mutation (0 available); any Braf mutation (58 available)
Tg(TPO-cre)1Shk mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• mice weigh about 50% less than wild-type littermates by weaning

homeostasis/metabolism
• by 5 weeks of age, serum TSH levels are about 500-fold greater than in wild-type mice
• by 5 weeks of age, serum T4 levels are decreased

neoplasm
• mice develop infiltrative papillary thyroid cancer with complete penetrance by 5 weeks of age
• tumors encompass the entire thyroid gland and have features of aggressive human papillary thyroid cancer with papillae lined by tall cells, with increased number of mitoses, nuclear clearing, and pseudonuclear inclusions
• administration of levothyroxine (L-T4) soon after birth for 3 weeks does not prevent the onset or alter the characteristics of papillary thyroid tumors
• administration of L-T4 for 3 weeks beginning at 5 weeks of age when all mice have tumors does not decrease the mitotic rate or alter the severity of the tumors
• mice treated with the MEK1/2 inhibitor PD325901 for 3 weeks beginning at 3 weeks of age exhibit a decrease in thyroid tumor volume and a modest reduction in proliferative index of tumors
• tumor cells frequently invade perithyroidal tissues
• 66% of tumors invade into surrounding skeletal muscle by 5 weeks and vascular invasion is common

endocrine/exocrine glands
• mice develop infiltrative papillary thyroid cancer with complete penetrance by 5 weeks of age
• tumors encompass the entire thyroid gland and have features of aggressive human papillary thyroid cancer with papillae lined by tall cells, with increased number of mitoses, nuclear clearing, and pseudonuclear inclusions
• administration of levothyroxine (L-T4) soon after birth for 3 weeks does not prevent the onset or alter the characteristics of papillary thyroid tumors
• administration of L-T4 for 3 weeks beginning at 5 weeks of age when all mice have tumors does not decrease the mitotic rate or alter the severity of the tumors
• mice treated with the MEK1/2 inhibitor PD325901 for 3 weeks beginning at 3 weeks of age exhibit a decrease in thyroid tumor volume and a modest reduction in proliferative index of tumors
• tumor cells frequently invade perithyroidal tissues
• 66% of tumors invade into surrounding skeletal muscle by 5 weeks and vascular invasion is common
• mice are euthyroid at P3, however by 5 weeks of age, mice are hypothyroid

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
thyroid gland papillary carcinoma DOID:3969 OMIM:188550
J:168249


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory